Effect of amlodipine benzenesulfonate combined with atorvastatin on blood pressure and lipid levels in patients with hyperlipidemia and hypertension
苯磺酸氨氯地平联合阿托伐他汀治疗高脂血症伴高血压对患者血压、血脂水平的影响

摘要

目的 为提高高脂血症伴高血压疾病治疗效果，本课题将围绕苯磺酸氨氯地平联合阿托伐他汀治疗的临床效果进行观察，分析对患者血压、血脂水平的影响。方法 实验时间跨度为期一年，于2024年4月开始，至2025年4月结束，选择该期间收治的脂血症伴高血压患者作为实验观察主体，选入人数80例，借助随机数字表方法（计算机生成序列形式）将所有患者分成两组，即观察组（苯磺酸氨氯地平联合阿托伐他汀治疗n=40）、对照组（苯磺酸氨氯地平治疗n=40），统计治疗前及治疗后16周相关数据指标，利用SPSS系统完成分析对比，观察结果差异表现。结果 统计结果显示，两组患者治疗前相关指标无明显差异P＞0.05，治疗后16周观察组患者血压水平（SBP、DBP）、血脂水平（TC、TG、LDL-C、HDL-C）均优于对照组P＜0.05，心血管事件发生率低于对照组P＜0.05，两组不良反应发生率数据P＞0.05，无明显差异。结论 高脂血症伴高血压患者实施苯磺酸氨氯地平联合阿托伐他汀治疗可明显提高临床疗效，改善患者血压、血脂水平，降低心血管事件发生风险，且安全性良好，值得采纳。

Abstract

Objective To improve treatment outcomes for hyperlipidemia-associated hypertension, this study investigated the clinical efficacy of amlodipine besylate combined with atorvastatin, analyzing its effects on patients' blood pressure and lipid levels.
Methods The study spanned one year (April 2024 to April 2025), enrolling 80 patients with hyperlipidemia-associated hypertension. Using a computer-generated random sequence, participants were divided into two groups: the observation group (n=40) receiving amlodipine besylate and atorvastatin, and the control group (n=40) receiving amlodipine besylate alone. Data from pre-treatment and 16-week post-treatment measurements were collected and analyzed using SPSS for statistical comparison.
Results Pre-treatment data showed no significant differences between groups (P>0.05). However, after 16 weeks, the observation group demonstrated better blood pressure (SBP, DBP) and lipid profiles (TC, TG, LDL-C, HDL-C) compared to the control group (P<0.05). Both groups also showed lower cardiovascular event rates (P<0.05), while adverse reaction rates remained comparable (P>0.05).
Conclusion   Amlodipine besylate combined with atorvastatin significantly improves clinical outcomes for hyperlipidemia-associated hypertension patients, effectively lowering blood pressure and lipid levels while reducing cardiovascular event risks. The treatment demonstrates good safety profile and is recommended for clinical adoption.